Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.
You may also be interested in...
Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly
Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco
Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly
Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco
Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk
A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.